Global pharmaceutical company moves into life sciences hub White City Place

invoX Pharma Ltd (invoX), a global biopharmaceutical company, has agreed to lease 2,500 sq ft as its headquarters in the WestWorks building at White City Place, part of the White City Innovation District with Imperial College London.

invoX’s mission is to be a fully integrated biopharmaceutical company with an advancing pipeline of innovative products addressing unmet healthcare needs, worldwide.  At its core, the Company aspires to improve patients’ lives by creating access to innovative medicine.  invoX Pharma Ltd is a wholly-owned subsidiary of Sino Biopharmaceutical Limited, a global top 50 pharmaceutical company with more than 24,000 employees. invoX's international centre of excellence in antibody research and clinical development is based in Cambridge which is a part of the Golden Triangle with Oxford and London universities.

Ben Toogood, CEO of invoX, said: “We are excited to be moving into the life sciences hub at White City Place with so many global and UK leading pharmaceutical and biotech companies like Novartis, Takeda, Autolus and Engitix as neighbours.  invoX is well on its way, through multiple acquisitions and investments, to create a scalable platform to build a portfolio of promising clinical and pre-clinical stage drug candidates.  We recently completed the acquisition of F-star therapeutics, a clinical-stage biopharmaceutical company pioneering bispecific antibodies in immunotherapy, accelerating the build of our pipeline.  We believe these programs have the potential to improve people’s lives by creating access to innovative medicine across some of our key therapeutic areas including oncology and respiratory.”

David Camp, CEO of Stanhope, said: “Together with our partner and owner of White City Place, Cadillac Fairview, we are delighted to welcome another innovative life sciences company to the WestWorks building.  White City Place has rapidly become a leading life sciences hub and, as part of the White City Innovation District, is competing on the global stage at the cutting edge of sustainable development.”

Stanhope and Cadillac Fairview have already attracted to White City Place numerous major life science occupiers, Novartis, Autolus, Takeda, Engitix, Synthace and Vivan Therapeutics, totalling over 130,000 sq ft.  Stanhope and its partners Mitsui Fudosan and AIMCo are developing the Gateway development at White City Place with two buildings now complete, which is helping to transform White City into a global economic hotspot for STEM.